Vaxil Bio Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VXL.V research report →
Companywww.vaxil-bio.com
Vaxil Bio Ltd. , a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma.
- CEO
- Gadi Levin
- IPO
- 2010
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $617.02K
- P/E
- 1.69
- P/S
- 0.00
- P/B
- 0.66
- EV/EBITDA
- 0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 62.96%
- ROIC
- -13.70%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $522.00K · 393.26%
- EPS
- $0.18 · 13946.15%
- Op Income
- $-179,000
- FCF YoY
- 29.17%
Performance & Tape
- 52W High
- $0.33
- 52W Low
- $0.13
- 50D MA
- $0.20
- 200D MA
- $0.17
- Beta
- -1.26
- Avg Volume
- 2.00K
Get TickerSpark's AI analysis on VXL.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VXL.V Coverage
We haven't published any research on VXL.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VXL.V Report →